Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Fresolimumab [USAN:INN]
RN: 948564-73-6
UNII: 375142VBIA


  • An anti-TGF-beta antibody in phase I clinical trials (2011) for treatment-resistant primary focal segmental glomerulosclerosis.

    NCI: A pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) -beta 1, 2 and 3 with potential antineoplastic activity. Fresolimumab binds to and inhibits the activity of all isoforms of TGF-beta, which may result in the inhibition of tumor cell growth, angiogenesis, and migration. TGF-beta, a cytokine often over-expressed in various malignancies, may play an important role in promoting the growth, progression, and migration of tumor cells. (NCI Thesaurus)

Classification Code

  • Idiopathic Pulmonary Fibrosis, Focal Segmental Glomerulosclerosis,and Cancer
* denotes mobile formatted website

Links to Resources

Names and Synonyms

Name of Substance

  • Fresolimumab
  • Fresolimumab [USAN:INN]


  • anti-Transforming Growth Factor-beta
  • Fresolimumab
  • GC 1008
  • GC1008
  • UNII-375142VBIA

Registry Numbers

CAS Registry Number

  • 948564-73-6


  • 375142VBIA

System Generated Number

  • 0948564736